Defining a Healthy Human Gut Microbiome: Current Concepts, Future Directions, and Clinical Applications

Bäckhed, Fredrik; Fraser, Claire M.; Ringel, Yehuda; Sanders, Mary Ellen; Sartor, R. Balfour; Sherman, Philip M.; Versalovic, James; Young, Vincent B.; Finlay, B. Brett

doi:10.1016/j.chom.2012.10.012

Cited by 668 publications

(561 citation statements)

References 81 publications

Supporting

Mentioning

526

Contrasting

Unclassified

Order By: Relevance

“…Os tecidos imunes presentes no trato gastrointestinal constituem a maior e mais complexa fracção do sistema imunológico humano 16 . No intestino, a microbiota tem a função de "educar" o sistema imunológico e prevenir infecções patogênicas, e seu benefício se estende por outros órgãos, inclusive os pulmões 17 .…”

Section: Imunidadeunclassified

“…A microbiota humano estabelece no início da vida (no parto) sofrendo alterações desde o nascimento (idade gestacional, tipo de parto -parto vaginal ou parto cesariano) e ao longo da vida, influenciado por fatores como idade, alimentação, localização geográfica, o consumo de suplementos e fatores ambientais 16,29,30 . Além das doenças inflamatórias e autoimunes, existem outras doenças crônicas que podem ser afetadas pela comunidade microbiana do intestino.…”

Section: Fatores Determinantes Da Microbiotaunclassified

“…A ingestão de probióticos beneficia também os indivíduos saudáveis, evidências sugerem que os probióticos tem função de reduzir o risco de doenças infecciosas e infecções do trato respiratório superior 34 . Os probióticos atuam afetando a composição e a função da microbiota, portanto, o consumo de probióticos pode exercer um efeito benéfico à saúde, mesmo não sendo visível a alteração na composição da microbiota intestinal 16 .…”

Section: Tratamentos Probióticosunclassified

See 2 more Smart Citations

A importância da microbiota no organismo humano e sua relação com a obesidade

Ramirez¹

2018

Int J Nutrol

View full text Add to dashboard Cite

Não há conflito de interesseA importância da microbiota no organismo humano e sua relação com a obesidade 1 Ana Valeria Garcia Ramirez RESUMOEste trabalho é uma revisão bibliográfica com o objetivo de descrever a Importância da microbiota no organismo humano e sua relação com a obesidade. Foram realizadas compilações bibliográficas de artigos científicos originais e de revisão em revistas indexadas, Arquivos Brasileiros de Cardiologia, Scielo PubMed/Medline, SeCS. O trabalho descreveu que a microbiota é uma população de organismos microscópios que habitam o corpo humano. A microbiota intestinal influencia nas doenças gastrointestinais, e em uma variedade de condições imunológicas, como o diabetes mellitus tipo1, doenças cardiovasculares, doenças desmielinizantes autoimunes, alergia, asma, e na obesidade. Há uma associação entre a microbiota intestinal e o peso corporal, havendo uma modificação na composição das bactérias intestinais em obesos diferente das pessoas com IMC normal. O aumento do número de microrganismo promotores da saúde no trato gastrointestinal pode ser feito pela alimentação com prebióticos e probióticos, os quais modificam a composição da microbiota, formando uma barreira contra as bactérias ruins do ecossistema. O trabalho mostrou que com a integridade intestinal é possível evitar o surgimento de doenças impedindo a entrada de microrganismos patógenos e antígenos.Palavras Chaves: microbiota intestinal, obesidade, sobrepeso, metabolismo energético, imunidade. ABSTRACTThis paper is a bibliographic review aiming to describe the importance of microbiota in the human organism and its relationship with obesity. Original scientific articles and reviews from indexed journals such as Brazilian Cardiology articles, Scielo PubMed/Medline, SeCs were compiled. The present work described that microbiota is a population of microscopic organisms that live into the human body. Intestinal microbiota influences gastrointestinal diseases and a great variety of immunological conditions such as, diabetes mellitus type I, cardiovascular diseases, autoimmune demyelinating diseases, allergy, asthma and obesity. There is a close association between intestinal microbiota and body weight due to a modification in bacterial composition of obese people which is different from those with normal BMI. The increase in the number of health promoting microorganisms in the gastrointestinal tract may be achieved by eating prebiotic and probiotic food. They change microbiota composition by creating a barrier against bad bacteria from the ecosystem. Such paper has demonstrated that when preserving intestinal integrity, it is possible to avoid the occurrence of diseases by preventing the entrance of pathogenic and antigenic microorganisms.

show abstract

Section: Imunidadeunclassified

Section: Fatores Determinantes Da Microbiotaunclassified

Section: Tratamentos Probióticosunclassified

See 1 more Smart Citation

A importância da microbiota no organismo humano e sua relação com a obesidade

Ramirez¹

2018

Int J Nutrol

View full text Add to dashboard Cite

show abstract

“…A study on the consumption of a probiotic yogurt revealed the changes in expression of microbiome-encoded enzymes (related to carbohydrate metabolism), but no impact was found on microbial populations in faeces [59]. Several possibilities for the use of probiotics in dysbiosis conditions are there that may include use of a modified consortium or genetically engineered bacteria for targeted, enhanced benefits [59,60].…”

Section: Human Innate Gut Microbiota and Its Variationmentioning

confidence: 99%

“…However, it is still not clear to the researchers if prebiotic involvement promotes constancy in the population or results only in temporary shifts of population that are beneficial [62]. Correspond a prebiotic with a probiotic (forming a synbiotic) may be a fresh approach to make dietary-induced changes in the gut microbiota [60].…”

Section: Human Innate Gut Microbiota and Its Variationmentioning

confidence: 99%

Health and environmental applications of gut microbiome: a review

Chatterjee

Datta

Sharma

et al. 2017

Ecological Chemistry and Engineering S

View full text Add to dashboard Cite

Life on Earth harbours an unimaginable diversity of microbial communities. Among these, gut microbiome, the ecological communities of commensal, symbionts (bacteria and bacteriophages) are a unique assemblage of microbes. This microbial population of animal gut helps in performing organism's physiological processes to stay healthy and fit. The role of these microbial communities is immense. They continually maintain interrelation with the intestinal mucosa in a subtle equilibrium and help the gut for different functions ranging from metabolism to immunologic functions like upgradation of nutrient-poor diets, aid in digestion of recalcitrant food components, protection from pathogens, contribute to inter-and intra-specific communication, affecting the efficiency as disease vectors etc. The microbial diversity in the gut depends upon environmental competition between microbes, their sieving effects and subsequent elimination. Due to wide diversity of anatomy and physiology of the digestive tracts and food habits, the gut microbiome also differs broadly among animals. Stochastic factors through the history of colonization of the microbiome in a species and in situ evolution are likely to establish interspecies diversity. Moreover, the microbes offer enormous opportunity to discover novel species for therapeutic and/or biotechnological applications. In this manuscript, we review the available knowledge on gut microbiome, emphasising their role in health and health related applications in human.

show abstract

Limosilactobacillus reuteri 6475 and Prevention of Early Postmenopausal Bone Loss

Gregori,

Pivodic,

Magnusson

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceDaily supplementation with the probiotic Limosilactobacillus reuteri ATCC PTA 6475 (L reuteri) vs placebo has previously been demonstrated to reduce bone loss in an estrogen deficiency mice model and older women, although the magnitude of the effect was small. We hypothesized that long-term treatment with L reuteri could result in clinically relevant skeletal benefits in postmenopausal osteoporosis.ObjectiveTo evaluate whether daily supplementation with L reuteri vs placebo could reduce early postmenopausal bone loss and whether the effects remained or increased over time during 2 years of treatment.Design, Setting, and ParticipantsA double-blind, randomized, placebo-controlled clinical trial was conducted between December 4, 2019, and October 6, 2022, at a single center in Gothenburg, southwestern Sweden. Participants were recruited by online advertisements, and letters were sent to 10 062 women aged 50 to 60 years. Responding women (n = 752) underwent telephone screening, resulting in 292 women being invited to a screening visit. Of those who were screened, 239 women met all inclusion criteria and had no exclusion criteria.InterventionsCapsules with L reuteri in 2 doses, 5 × 108 (low dose) or 5 × 109 (high dose) colony-forming units, taken twice daily or placebo were administered. All capsules also included cholecalciferol, 200 IU.Main Outcomes and MeasuresThe primary outcome was the relative change in tibia total volumetric bone mineral density (vBMD) over 2 years. Secondary outcomes included relative change in areal BMD of the lumbar spine and total hip, bone turnover markers C-terminal telopeptide cross-links of collagen type I and type I procollagen intact N-terminal propeptide, as well as tibia trabecular bone volume fraction and cortical vBMD. Both intention-to-treat and per-protocol analyses were conducted.ResultsA total of 239 postmenopausal women (median age, 55 [IQR, 53-56] years) were included. Tibia vBMD (primary outcome), hip and spine vBMD, and tibia cortical area and BMD decreased significantly in all groups, with no group-to-group differences (percent change tibia vBMD high dose vs placebo least-squares means, −0.08 [95 CI, −0.85 to 0.69] and low dose vs placebo least-squares means, −0.22 [95% CI, −0.99 to 0.55]). There were no significant treatment effects on any other predefined outcomes. A prespecified sensitivity analysis found a significant interaction between body mass index (BMI) and treatment effect at 2 years. No significant adverse effects were observed.Conclusions and RelevanceIn this randomized clinical trial of 239 early postmenopausal women, supplementation with L reuteri had no effect on bone loss or bone turnover over 2 years. The observed interaction between BMI and treatment effect warrants further investigation.Trial RegistrationClinicalTrials.gov Identifier: NCT04169789

show abstract

Defining a Healthy Human Gut Microbiome: Current Concepts, Future Directions, and Clinical Applications

Cited by 668 publications

References 81 publications

A importância da microbiota no organismo humano e sua relação com a obesidade

A importância da microbiota no organismo humano e sua relação com a obesidade

Health and environmental applications of gut microbiome: a review

Limosilactobacillus reuteri 6475 and Prevention of Early Postmenopausal Bone Loss

Contact Info

Product

Resources

About